Overview

Raised to Date: Raised: $1,025,275

Deal Terms

Investment Momentum

Company Profile

Deal Summary

Financials

Total Commitments ($USD)

Platform

StartEngine

Start Date

06/16/2022

Close Date

12/14/2022

Min. Goal

$10,000

Max. Goal

$5,000,000

Min. Investment

$400

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    

Price Per Share

$2.00

Pre-Money Valuation

$48,772,314

Rolling Commitments ($USD)

Status

Funded

Reporting Date

12/30/2022

Days Remaining

Funded

% of Min. Goal

Funded

% of Max. Goal

Funded

Likelihood of Max

Funded

Avg. Daily Raise

$5,696

# of Investors

425

Momentum

Funded

Create a free account today to gain access to KingsCrowd analytics.

Logos provided by Clearbit

AiViva

Year Founded

2020

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Newport Beach, California

Business Type

High Growth

Company Website

AiViva, with a valuation of $48.8 million, is raising funds on StartEngine. It is a biotechnology company that has created proprietary technology and new treatments in the fields of urology, oncology, dermatology, and ophthalmology. The JEL technology of AiViva enhances the benefits of drugs and prolongs their therapeutic effects, thus reducing the treatment frequency and improving outcomes. AiViva is conducting four clinical trials focused on wet AMD, non-melanoma skin cancer, and prostate disorders. Diane Tang-Liu founded AiViva in February 2020. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $5,000,000. The campaign proceeds will be used for research and development and the advancement of novel treatment paradigms.

Summary Profit and Loss Statement

	Most Recent Year	Prior Year
Revenue	$17,000	$153,000
COGS	$0	$0
Tax	$4,070	$800
Net Income	$-3,960,872	$-4,542,477

Summary Balance Sheet

	Most Recent Year	Prior Year
Cash	$3,601,734	$5,419,620
Accounts Receivable	$0	$0
Total Assets	$4,583,591	$8,589,570
Short-Term Debt	$437,051	$597,651
Long-Term Debt	$23,892	$0
Total Liabilities	$460,943	$597,651

Financials as of: 06/16/2022

Create a free account today to gain access to KingsCrowd analytics.

AiViva Founder Dr. Diane Tang-Liu on Advancing Medicine

It can be difficult and time-consuming to manage chronic and degenerative conditions. One example is wet age-related macular degeneration (AMD), a condition that causes abnormal blood vessel growth in the eye. These vessels leak fluid and scar the eye, affecting a person’s vision. The treatment for this condition is generally a monthly injection of eye medication.

AiViva has developed a treatment for this and other eye, skin, urinary tract, and cancer conditions that would provide more long-term relief. We spoke with AiViva founder and CEO Dr. Diane Tang-Liu about this new treatment and its potential applications.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview